Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes under its existing shelf registration. The notes, denominated in euros, are offered in three tranches: €700 million at 3.200% due 2032, €800 million at 3.350% due 2036, and €1 billion at 3.550% due 2044. Interest on these notes will be paid annually beginning June 1, 2024. The notes are expected to be listed on the New York Stock Exchange and are intended to be used for general corporate purposes, which may include funding the acquisition of Shockwave Medical, Inc. The offering is managed by a consortium of banks, including J.P. Morgan, Citigroup, and Deutsche Bank, acting as joint book-running managers. The issuance is subject to customary closing conditions and is expected to settle on May 20, 2024.

Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes under its existing shelf registration. The notes, denominated in euros, are offered in three tranches: €700 million at 3.200% due 2032, €800 million at 3.350% due 2036, and €1 billion at 3.550% due 2044. Interest on these notes will be paid annually beginning June 1, 2024. The notes are expected to be listed on the New York Stock Exchange and are intended to be used for general corporate purposes, which may include funding the acquisition of Shockwave Medical, Inc. The offering is managed by a consortium of banks, including J.P. Morgan, Citigroup, and Deutsche Bank, acting as joint book-running managers. The issuance is subject to customary closing conditions and is expected to settle on May 20, 2024.